• Home
  • Firm
  • Strategies
  • Portfolio
  • Team
  • Insights
  • Investors
  • Contact
  • Click to open the search input field Click to open the search input field Search
  • Menu Menu

Day Three Labs news feed

Tag Archive for: DTL

Day Three Labs Acquires Revolutionary Pharmaceutical-Grade Cannabinoid Infusion Technology

January 11, 2022

DENVER, Jan. 11, 2022 /PRNewswire/ — Day Three Labs (DTL), a cannabinoid CPG ingredient manufacturer specializing in the development and commercialization of novel cannabis product solutions, has acquired a patented pharmaceutical-grade cannabinoid infusion technology developed by a leading Israeli bioscience company. The deal was led and structured by KEY Investment Partners with participation from Phyto […]

Read more
https://keyinvestmentpartners.com/wp-content/uploads/2026/08/KEY_Logo_Horizontal_Color_Transparent_1568w.svg 0 0 Key Investment Partners https://keyinvestmentpartners.com/wp-content/uploads/2026/08/KEY_Logo_Horizontal_Color_Transparent_1568w.svg Key Investment Partners2022-01-11 12:12:432022-01-11 12:12:43Day Three Labs Acquires Revolutionary Pharmaceutical-Grade Cannabinoid Infusion Technology

Categories

  • KEY Insights
  • Newsletter
  • Press
  • White Paper
Unlocking Cannabis Podcast

Subscribe

Sign up to receive news and updates.

Follow us on Facebook

Subscribe

Sign up to receive news and updates.

Menu

  • Home
  • Firm
  • Strategies
  • Portfolio
  • Team
  • Insights
  • Contact
  • Legal

What’s New

  • KEY Newsletter – Federal Rescheduling April 2026
  • KEY Newsletter – 2026 Update and Outlook
  • Cannabis Investing: 2026 Update – Focus on the Controllables

Headquarters

KEY Investment Partners LLC
1550 Larimer Street, Suite 1084
Denver, Colorado 80202

© 2026 KEY Investment Partners LLC | Terms Of Use
  • Link to LinkedIn
  • Link to Facebook
  • Link to Instagram
  • Link to X
Scroll to top Scroll to top Scroll to top

The information on this website is provided for general informational purposes only and does not constitute an offer to sell, or a solicitation of an offer to buy, any security or investment product. Any such offer or solicitation may be made only by means of definitive offering documents provided to qualified investors. Past performance is not indicative of future results.